#438: QMSR Mythbusters Episode

Global Medical Device Podcast · 22 Dec 2025 · 19m · Episode 438

What this episode covers

Host Etia Nichols from Greenlight Guru explains the FDA's new Quality Management System Regulation (QMSR), which replaces 21 CFR Part 820 and incorporates ISO 13485:2016 by reference, with a mandatory enforcement date of February 2, 2026. Nichols debunks the myth that the Device Master Record (DMR), Design History File (DHF), and Device History Record (DHR) are being eliminated, clarifying they are mapped to the Medical Device File (MDF), Design and Development File (DDP), and Batch or Lot Record respectively. She highlights three critical shifts: the explicit integration of lifecycle risk management as the 'DNA' of the QMS, the loss of audit privilege making internal records inspectable, and retained US-specific requirements like UDI in complaint records and extended record retention.

Other shows on the same ground, closest first.

  • Let's Combinate · 10m

    198 - QMSR Explained, ISO 13485 Compared, and 5 Key Things You Might’ve Missed

    Subhi Saadeh, host of Let's Combinate and Quality Professional, breaks down five critical aspects of the FDA's new Quality Management System Regulation (QMSR). He explains that while QMSR harmonizes with ISO 13485, it retains 21 CFR 820 with FDA-specific overlays like UDI and complaint handling, and removes previous exemptions for certain manufacturers. Saadeh emphasizes that risk management remains mandatory despite not being explicitly named in the text, and warns that companies must complete gap assessments and training before the February 2, 2026 compliance deadline.

  • Let's Combinate · 32m

    130 - QMSR Changes to Traceability/Reporting, Independent Reviewer & Risk Management, Learning New Regulations and MDSAP with Aaron Snyder

    Aaron Snyder, VP of Quality Assurance at Allotex and AAMI Faculty member, explains the FDA's Quality Management System Regulation (QMSR) and its incorporation of ISO 13485. He details specific changes to traceability, including the requirement to meet 21 CFR Part 821 (Medical Device Tracking) and Part 830 (UDI) in addition to ISO requirements, and new FDA-specific controls for records, packaging, and labeling. Snyder contrasts FDA inspection techniques, which focus on finding non-compliance through deep dives into complaint and service records, with ISO surveillance audits that verify conformity. He also discusses the impact of QMSR on MDSAP companies, noting that while harmonization simplifies compliance for large firms, smaller US-only companies face more work to adopt the process approach and explicit risk management.

  • Let's Combinate · 42m

    125 - Unpacking the Quality Management System Regulation(QMSR) Final Rule with Subhi Saadeh

    Subhi Saadeh, host of the Combinate Podcast and Quality Professional, conducts an active reading of the FDA's Quality Management System Regulation (QMSR) Final Rule to unpack changes to 21 CFR 820 and 21 CFR 4. He details the harmonization of the Quality System Regulation (QSR) with ISO 13485, highlighting new sections like 820.10 and 820.45, and the reclassification of previous QSR subparts as 'reserved.' Saadeh also analyzes FDA comments regarding combination products, component manufacturers, and the practical implications of aligning US regulations with global standards to reduce industry inefficiency.

  • Let's Combinate · 9m

    256 - The New FDA Inspection Playbook: Where to Start with QMSR

    Subhi Saadeh, founder of Let’s Combinate, introduces a four-part series on FDA inspection readiness under the new Quality Management System Regulation (QMSR), explaining how the retired QSIT framework has been replaced by Compliance Program 7382.850. He highlights advice from former FDA investigator Eric Pittman, who advises industry to focus exclusively on Section III of compliance programs as the primary roadmap for inspections. The episode details the shift from QSIT’s four major subsystems to six QMS areas, emphasizing a risk-based approach where investigators evaluate product risks and control effectiveness.

  • Let's Combinate · 48m

    127 - BIG Risk Management Changes in QMSR, Risk Acceptability, Risk Policy & Explaining vs. Justifying Risk Decisions with Naveen Aggarwal

    Naveen Aggarwal, founder of Creative Analytic Solutions, explains that the QMSR final rule does not mandate ISO 14971 but requires risk management to be integrated into ISO 13485 quality systems, shifting FDA inspection focus from procedural compliance to risk-based decision-making. He highlights that small and mid-size companies face significant costs to transition, while large firms must overcome the challenge of linking risk outputs to design inputs and post-market data. Aggarwal advises against standalone risk policies, suggesting instead that companies integrate risk acceptability criteria into their existing quality policies and use clear, binary (red/green) risk matrices rather than ambiguous yellow zones.

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Global Medical Device Podcast. The episode itself belongs to its publisher.